Entries by sandbox

Eyenovia Reports Third Quarter 2021 Financial Results

Eyenovia Reports Third Quarter 2021 Financial Results On track with VISION-2 phase 3 presbyopia trial and expedited resubmission of MydCombi™ New Drug Application as a drug/device combination in early 2022 Current cash resources anticipated to be sufficient to cover MydCombi NDA resubmission, completion of Phase 3 MicroLine program, and completion of manufacturing facility Company to […]

Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator @AAO 2021 Meeting

Discussion to Include Future Potential Treatment Options, Including MicroPine (atropine ophthalmic spray), for reduction of myopia progression in pediatrics NEW YORK—November 8, 2021—Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology, today announced that Dr. Sean Ianchulev, Chief Executive […]

Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia

Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022  Presbyopia represents a multi-billion-dollar market opportunity in the U.S. alone NEW YORK—November 4, 2021—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print […]

Eyenovia Announces Reclassification of MydCombi™ as Drug-Device Combination Product by FDA

Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review of all drugs that are in delivery systems, including eye dropper bottles  Company received Complete Response Letter with additional requests and is preparing necessary documents for expedited resubmission  NEW YORK—October 25, 2021—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline […]

Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors

NEW YORK–(BUSINESS WIRE)–Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the appointment of renowned ophthalmologist and scientific leader, Julia Haller, M.D., to its Board of Directors. “We are delighted to welcome Dr. Haller to our Board of […]

Eyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase

Eyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase   NEW YORK–(BUSINESS WIRE)–Jan. 26, 2021– Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. David Wirta will speak at the Ophthalmology Innovation Summit Presbyopia Innovation Showcase on January 28th. Dr. Wirta’s presentation will […]

Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia

Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Topline Results Expected First Half of 2021 December 16, 2020 07:00 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a […]

Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis

Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually December 29, 2020 07:00 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has submitted […]

Eyenovia To Report Third Quarter 2020 Results

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) — Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will release financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020, after market close. Following the release, Eyenovia’s Chief Executive Officer and Chief […]